Figure 4 from Screening FDA-Approved Oncology Drugs with Three-Dimensional Spheroids Identifies Romidepsin as a Therapeutic Candidate for Osteosarcoma
Year: 2025
Type: other
Abstract: Romidepsin has the largest overall therapeutic index of all 13 hits from the initial screen. Data represent dose–response experiments for top 13 hits from initial screen. Ratios of TD50/sarcosphere (Sarco) ED50 reflect therapeutic indices with NHOst and non-transformed human SAEC. White on the color scale is set at the median of the overall row means, shown in the first column. TD50s, doses that reduce metabolic activity of NHOst and SAEC by 50%, are shown in Supplementary Figs. S5A and S6A. The TD50/ED50 ratios are shown in Supplementary Figs. S5B–S5D and S6B–S6D. TD50s were determined in N = 3 independent dose–response experiments with each drug. Each experiment included at least three culture wells per group. ED50s, doses that reduce metabolic activity of 143B, LM7, or MG63.3-GFP sarcospheres by 50%, are shown in Supplementary Fig. S1B–S1D and Supplementary Table S3.
Authors: Emily E. Seiden, Spencer M. Richardson, Leah A. Everitt, Gabrielle J. Knafler, Alyssa L. Walker, Venetia A. Whiteside, Divya Pillutla, Shrey Ramnath, Gavin P. Kinsella, Piper A. Wilburn, James D. Buschbach, Deep A. Gandhi, M. Reza Saadatzadeh, L. Daniel Wurtz, Patrick J. Getty, Sheldon L. Padgett, Rance M. Gamblin, Michael O. Childress, Christopher M. Fulkerson, Maegan L. Capitano, Karen E. Pollok, Christopher D. Collier, Edward M. Greenfield
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4415191465
Cites:
Cited by:
Related to: